3,4-Methylenedioxymethamphetamine (MDMA), but not morphine, alters APP processing in the rat brain. 2007

János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
Department of Psychiatry and Alzheimer's Disease Research Centre, Albert Szent-Györgyi Center for Medical and Pharmaceutical Sciences, Faculty of Medicine, University of Szeged, Szeged, Hungary. kalmanj@nepsy.szote.u-szeged.hu

The abuse of drugs such as opioids and 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') can have detrimental effects on the cognitive functions, but the exact molecular mechanism whereby these drugs promote neurodegeneration remains to be elucidated. The major purpose of the present pilot study was to determine whether the chronic in-vivo administration of morphine (10 mg/kg) or MDMA (1 mg/kg) to rats can alter the expression and processing of amyloid precursor protein (APP), the central molecule in the proposed pathomechanism of Alzheimer's disease. MDMA treatment significantly decreased the production of APP in the cytosolic fraction of the brain cortex. A concomitant 25% increase was found both in the beta-secretase (BACE) and APP mRNA levels (108%). In contrast, in the applied single dosage chronic morphine treatment did not influence either the APP and BACE protein levels or the APP mRNA production. These results indicate that the chronic use of 'ecstasy', but not morphine, may be harmful via a novel mode of action, i.e. by altering the APP expression and processing in the brain.

UI MeSH Term Description Entries
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D003720 Densitometry The measurement of the density of a material by measuring the amount of light or radiation passing through (or absorbed by) the material. Densitometries
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D005260 Female Females
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D016564 Amyloid beta-Protein Precursor A single-pass type I membrane protein. It is cleaved by AMYLOID PRECURSOR PROTEIN SECRETASES to produce peptides of varying amino acid lengths. A 39-42 amino acid peptide, AMYLOID BETA-PEPTIDES is a principal component of the extracellular amyloid in SENILE PLAQUES. Amyloid A4 Protein Precursor,Amyloid Protein Precursor,beta-Amyloid Protein Precursor,Amyloid beta Precursor Protein,Protease Nexin 2,Protease Nexin II,Amyloid beta Protein Precursor,Nexin 2, Protease,Nexin II, Protease,beta Amyloid Protein Precursor,beta-Protein Precursor, Amyloid

Related Publications

János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
February 1998, Acta crystallographica. Section C, Crystal structure communications,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
January 2012, Cell journal,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
July 1998, Psychopharmacology,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
November 1989, Pharmacology, biochemistry, and behavior,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
June 2023, Environmental toxicology and pharmacology,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
August 1986, European journal of pharmacology,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
December 2001, Current psychiatry reports,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
January 2013, Substance abuse and rehabilitation,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
August 2000, European journal of pharmacology,
János Kálmán, and Annamária Bjelik, and Marietta Hugyecz, and Júlia Tímár, and Zsuzsanna Gyarmati, and Marianna Zana, and Zsuzsanna Fürst, and Zoltán Janka, and Zoltán Rakonczay, and Zoltán Horváth, and Magdolna Pákáski
April 2006, Synapse (New York, N.Y.),
Copied contents to your clipboard!